Abstract 18163: A Prospective Study of Fatty Liver Index and Incident Hypertension
Background: Although non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome, its influence on hypertension development is poorly understood. Hypothesis: We investigated whether fatty liver disease, as assessed by the fatty liver index (FLI), could predict the development of hypertension independently of systemic insulin resistance and inflammatory status.
Methods: Prospective cohort study of 1,521 adults (484 men and 1037 women) aged 40 to 70 years without baseline hypertension examined in 2005 to 2008 as a baseline and 2008 to 2011 for follow-up. An equation was used to calculate FLI and classify patients as follows: FLI<30, no NAFLD; FLI ≥60, NAFLD; and 31<FLI<59, intermediate FLI.
Results: During an average of 2.6 years of follow-up, 153 subjects (10.06 %) developed hypertension. FLI was positively associated with baseline blood pressure, homeostasis model assessment of insulin resistance (HOMA-IR), leptin, urinary albumin/creatinine excretion, and high sensitivity C-reactive protein (hsCRP). After adjustment for confounding factors, including markers of insulin resistance and systemic inflammation, the odds ratio (95% confidence interval) for the incident hypertension increased in a graded manner with FLI (<30 vs. 30-59 vs. ≥60= 1 vs. 1.77 [1.16-2.71] vs. 2.06 [1.09-3.89], respectively). Conclusions: NAFLD assessed by FLI was an independent risk factor for hypertension. Our findings suggest that FLI, a simple surrogate indicator of fatty liver disease, might be useful for identifying subjects at high risk for incident hypertension in clinical practice.
Author Disclosures: J. Kim: None. J. Lee: None. Y. Youn: None. M. Ahn: None. B. Yoo: None. S. Lee: None. J. Yoon: None.
- © 2015 by American Heart Association, Inc.